Back

Breast Care Center - Clinical Trials

Specialty Cancer Centers

New Patient Appointment

321.843.8370

Clinical Trials

  • The treating physician/investigator contacts Lilly when, based on

    To provide abemaciclib to eligible patients with recurrent, locally advanced, unresectable or metastatic breast cancer prior to commercial availability.

  • Pre-Test Genetic Education and Remote Genetic Counseling in Commu

    PRIMARY OBJECTIVES: I. To evaluate the efficacy of web-based pre-test genetic education (i.e. before receipt of tumor profile results) to increase knowledge (genetic knowledge and knowledge of test benefits and limitations). (Step 1) II. To evaluate the efficacy of web-based pre-test genetic education (i.e. before receipt of tumor profile results) to decrease distress (anxiety, depression and cancer specific worry) compared to usual care services in patients undergoing tumor profiling for advanced cancer. (Step 1) III. To evaluate the uptake of remote genetic counseling (Step 2) IV. To evaluate the uptake of germline testing among advanced cancer patients with a potential clinically significant incidental germline mutation identified through tumor profiling in the Molecular Analysis for Therapy Choice (MATCH) trial. (Step 2) SECONDARY OBJECTIVES: I. To evaluate potential moderators suggested by the self-regulation theory of health behavior (SRTHB) (e.g. test result, sociodemographic factors, health literacy, baseline knowledge or distress) to changes in knowledge of genetic disease and test benefits and limitations. (Step 1) II. To evaluate potential moderators suggested by the SRTHB (e.g test result, sociodemographic factors, health literacy, baseline knowledge or distress) to changes in distress in patients undergoing tumor profiling for advanced cancer. (Step 1) III. To evaluate factors associated with uptake of genetic counseling and germline testing. (Step 2) IV. To evaluate cognitive, affective and behavioral (communication to relatives) responses to confirmatory germline testing in advanced cancer patients with potential clinically significant incidental germline mutation identified in tumor profiling. (Step 2)

  • Pembrolizumab in Treating Patients With Triple-Negative Breast Ca

    To compare invasive disease-free survival (IDFS) of patients with triple-negative breast cancer (TNBC) who have either >= 1 cm residual invasive breast cancer and/or positive lymph nodes (> ypN+) after neoadjuvant chemotherapy randomized to receive 1 year of MK-3475 (pembrolizumab) adjuvant therapy compared to no MK-3475 (pembrolizumab), in both the entire study population and also in the PD-L1 positive subset. To compare the effects of MK-3475 (pembrolizumab) on overall survival (OS) and distant recurrence-free survival (DRFS) between the two randomized arms for the PD-L1 positive patients and then all patients. II. To assess the toxicity and tolerability of MK-3475 (pembrolizumab) in this patient population with or without radiation therapy

  • Phase 2 Study of Atezolizumab With or Without Entinostat in Patie

    Phase 1b (Dose Determination Cohort): To determine the dose-limiting toxicities (DLT) and maximum tolerated dose (MTD) or recommended Phase 2 dose (RP2D) of entinostat (SNDX-275) given in combination with atezolizumab. Phase 2 (Expansion Cohort): To perform an evaluation of the efficacy of entinostat at the RP2D in combination with atezolizumab in patients with aTNBC, as determined by the duration of progression-free survival (PFS) based on the local investigator’s assessment of progressive disease using Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) .

  • Phase I Open-Label of Talazoparib on Cardiac Patients

    To evaluate the effect of talazoparib on cardiac repolarization in patients with advanced solid tumors by assessing the QTc To assess the relationship between plasma talazoparib concentrations and the QTc

  • Phase I Open-Label Pharmacokinetics and Safety of Talazoparib

    To investigate the effect of mild, moderate or severe hepatic impairment on the PK of talazoparib following daily oral dosing for 22 consecutive days, in patients with advanced solid tumors.

  • Study of Ribociclib With Everolimus + Exemestane in HR+ HER2- Loc

    Determine the Clinical Benefit Rate (CBR) at 24 weeks amongst patients receiving triple therapy with ribociclib + everolimus + exemestane, for advanced/metastatic HR+, HER2-negative breast cancer following progression on CDK 4/6 inhibitor.

  • A Study of Abemaciclib (LY2835219) in Women With HR+, HER2+ Local

    The primary objective of this study is to compare the efficacy of abemaciclib plus trastuzumab plus fulvestrant and abemaciclib plus trastuzumab to standard-of-care single-agent chemotherapy of physician’s choice plus trastuzumab with respect to progression free survival (PFS).

  • Study of Ribociclib With Everolimus + Exemestane in HR+ HER2- Loc

    Determine the Clinical Benefit Rate (CBR) at 24 weeks amongst patients receiving triple therapy with ribociclib + everolimus + exemestane, for advanced/metastatic HR+, HER2-negative breast cancer following progression on CDK 4/6 inhibitor.

  • Molecular Analysis for Therapy Choice (MATCH)

    To evaluate the proportion of patients with objective response (OR) to targeted study agent(s) in patients with advanced refractory cancers/lymphomas/multiple myeloma.